|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 96 No. 3 (August 1), 2000:
pp. 1184-1186
BRIEF REPORT
Pure red cell aplasia due to parvovirus B19 in a patient treated
with rituximab
Vivek R. Sharma,
Donald R. Fleming, and
Stephen P. Slone
From the Division of Medical Oncology/Hematology, the
Department of Pathology, and the James Graham Brown Cancer Center,
University of Louisville, Louisville, KY.
Rituximab is a chimeric monoclonal antibody directed
against CD20 and used in the treatment of B-cell non-Hodgkin's
lymphoma. Due to its ability to deplete B lymphocytes, rituximab can
interfere with humoral immunity, causing it to be suppressed for
several months after treatment. The reported case depicts a serious
consequence of this effect of rituximab therapy: pure red cell aplasia
resulting from chronic parvovirus B19 infection. The point of interest
in this case is not only the association between rituximab therapy and
pure red cell aplasia, but the diagnostic and therapeutic utility of
the knowledge of parvovirus B19 as the likely etiologic link between
the two. Given the known efficacy of intravenous immunoglobulin (IVIg)
in the treatment of chronic parvovirus B19 infection, this therapy
can cure some of these patients and successfully render most others
transfusion-independent until recovery of their own humoral immune system.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
W. Yeo, T. C. Chan, N. W.Y. Leung, W. Y. Lam, F. K.F. Mo, M. T. Chu, H. L.Y. Chan, E. P. Hui, K. I.K. Lei, T. S.K. Mok, et al.
Hepatitis B Virus Reactivation in Lymphoma Patients With Prior Resolved Hepatitis B Undergoing Anticancer Therapy With or Without Rituximab
J. Clin. Oncol.,
February 1, 2009;
27(4):
605 - 611.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. H. Westhoff, F. Jochimsen, A. Schmittel, M. Stoffler-Meilicke, J. H. Schafer, W. Zidek, W. H. Gerlich, and E. Thiel
Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy
Blood,
September 1, 2003;
102(5):
1930 - 1930.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. W. Saville, M. C. Benyunes, P. S. Multani, H. M. Prince, K. Herbert, and D. Westerman
No clinical evidence for CD4+ cell depletion caused by rituximab
Blood,
July 1, 2003;
102(1):
408 - 409.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Zecca, B. Nobili, U. Ramenghi, S. Perrotta, G. Amendola, P. Rosito, M. Jankovic, P. Pierani, P. De Stefano, M. R. Bonora, et al.
Rituximab for the treatment of refractory autoimmune hemolytic anemia in children
Blood,
May 15, 2003;
101(10):
3857 - 3861.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P C Ng, K K M Lee, A F C Lo, C K Li, and T F Fok
Anti B cell targeted immunotherapy for treatment of refractory autoimmune haemolytic anaemia in a young infant
Arch. Dis. Child.,
April 1, 2003;
88(4):
337 - 339.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. E. Herbert, H. M. Prince, and D. A. Westerman
Pure red-cell aplasia due to parvovirus B19 infection in a patient treated with alemtuzumab
Blood,
February 15, 2003;
101(4):
1654 - 1654.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Wiestner, H. J. Cho, A. S. Asch, M. A. Michelis, J. A. Zeller, E. I. B. Peerschke, B. B. Weksler, and G. P. Schechter
Rituximab in the treatment of acquired factor VIII inhibitors
Blood,
October 16, 2002;
100(9):
3426 - 3428.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Ghazal
Successful treatment of pure red cell aplasia with rituximab in patients with chronic lymphocytic leukemia
Blood,
February 1, 2002;
99(3):
1092 - 1094.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Suzan, M. Ammor, and V. Ribrag
Fatal Reactivation of Cytomegalovirus Infection after Use of Rituximab for a Post-Transplantation Lymphoproliferative Disorder
N. Engl. J. Med.,
September 27, 2001;
345(13):
1000 - 1000.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Zecca, P. De Stefano, B. Nobili, and F. Locatelli
Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia
Blood,
June 15, 2001;
97(12):
3995 - 3997.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
